KRAS and non-small cell lung carcinoma: In addition to KRAS inhibitors targeting the G12C mutation, inhibitors targeting other mutations, such as G12D and G12V mutations, also have certain therapeutic effects on NSCLC caused by KRAS mutation (71, 72).